 - Determine the safety of adoptive immunotherapy comprising 2-methyl-3-butenyl-1-pyrophosphate-stimulated gamma delta gd T cells, zoledronate, and IL-2 after nephrectomy, especially with regard to the incidence and frequency of adverse events. 